11.30.23 -- Overcome Downstream Bottlenecks In LVV Production

Addressing the need to cost-effectively produce large quantities of CGTs is essential to expand access to these lifesaving treatments. Finding a CDMO partner with resources and extensive experience in the development and production of CGTs is a key step in achieving the scalable manufacture of safe, effective AAV-mediated gene therapies.

LVVs allow scientists to transfer genetic material specifically into particular cells. However, large-scale production and the complex purification process present a number of unique challenges, making it essential for developers to understand technical requirements and adhere to protocols to maximize vector recovery and ensure success.

In a quickly evolving and relatively new therapeutic area like cell and gene therapy (CGT), staying abreast of dynamic regulatory requirements is fundamental to success. Delve into the key factors that developers must consider to design and implement a successful analytical method development strategy in viral vector manufacturing.

Leverage the expansive knowledge and technical talent of our team along with our available and scalable capacity. We can initiate and maintain reliable supply for your early-phase clinical trials and beyond, delivering high-quality, cost-effective, and precise retroviral production services through producer cell lines and master cell bank expansion.

Accelerating your path through development to commercialization, we deliver high-quality, cost-effective, and precise GMP lentivirus production services. Learn how we can support you with the latest technologies from a state-of-the-art facility dedicated to the aseptic production of lentiviral vectors.